Sulbenicillin (disodium)

Sulbenicillin disodium is a semisynthetic α-sulfonylbenzylpenicillin antibiotic. Sulbenicillin disodium exerts antibacterial activity against multiple gram-negative rods. Sulbenicillin disodium inhibits primary and secondary platelet aggregation, serotonin release from platelets, and platelet adherence via platelet surface coating. Sulbenicillin disodium can be used for the research of Pseudomonas aeruginosa, Pseudomonas maltophilia, and Pseudomonas cepacia infections^[1][2][3]. In Vitro:Sulbenicillin disodium (50-200 μg/mL) binds to human albumin in vitro with an approximate 70% bound fraction in the clinically relevant concentration range of 50 to 200 μg/mL^[1].
Sulbenicillin disodium demonstrates in vitro antibacterial activity against clinical isolates of Proteus mirabilis (95% of strains have MIC₅₀ ≤6 μg/mL) and Pseudomonas aeruginosa (90% of strains have MIC₅₀ <20 μg/mL)^[1].
Sulbenicillin disodium (0.2-25 mM) inhibits ADP-, epinephrine-, and collagen-induced aggregation of human platelets in vitro, with a minimum effective concentration of 5 mM for inhibiting secondary ADP-induced aggregation and collagen-induced maximal aggregability^[3].
Sulbenicillin disodium (5-25 mM) inhibits [¹⁴C]-serotonin release from human platelets in vitro at 25 mM, with minimal effect at 5 mM^[3].